Download presentation
Presentation is loading. Please wait.
Published byClaude Collins Modified over 9 years ago
1
An Orthopod’s Perspective Adrian Beaumont Consultant Orthopaedic Surgeon Salisbury District Hospital
2
Size of Problem ? 25,000 deaths per year VTE in 40% to 60% joint replacements Fatal PE in 0.1% to 5% Inconsistent thromboprophylaxis Joint registry shows increasing use of mechanical and chemical methods
5
Hugh Owen Thomas 1834 - 1891
8
Fast Track Mobilisation No clear data on VTE risk Intuitively beneficial
9
Rudolf Virchov 1821 - 1902
16
Nice Guidelines 2010 Had orthopaedic input Risk assess Hip and knee replacements high risk Combined methods Oral agents (not aspirin) Duration ‘Opt out’ when bleeding risk
18
Evidence! Or Evidence? Cross trial comparisons Criteria End points Definitions Sponsored? Statistics Need Expert Interpretation
21
Anti-Embolism Stockings Often problematic for our patients Wounds, swelling etc Restricted movement Large legs
24
Hip Fractures Very common High mortality Immobility Delay to theatre Age
25
Lower Limb Casts Evidence if risk ? UK lags behind Europe Risk assess or risk forgetting Plymouth type scoring system LMWH prescribed at discretion Ongoing audit
29
Major Bleeding (EMEA) Fatal Bleeding Decrease Hb by 20 grams Transfusion 2 units blood Critical bleeding Leading to discontinuation At surgical site Leading to reoperation
32
Deep Infection Often disastrous Usually means implant removal
34
Summary The importance VTE recognised We have some knowledge of efficacy Variable but increasing prophylaxis The adverse effects must be considered Expert guidance needed There will be ongoing change
35
Thank You
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.